There is a growing need among decision-makers to understand the economic and financial value of interventions, as well as the clinical efficacy and effectiveness of such interventions.
This ‘value’, and the relationship between costs and benefits requires the consideration of the patient’s journey undergoing a new intervention and comparing this journey with what is current standard practice. Capturing this value is a complex and multifaceted approach that requires assessing not only the direct benefit of the intervention, as ascertained by the efficacy of the intervention, but also additional benefits such as the quality of life of the patient, the healthcare activity that the disease or its treatment generates, costs incurred and any additional ‘downstream’ events that may occur.
To best answer these ‘value’ questions, it may be necessary and /or beneficial to collect the necessary economic evidence concurrently within a clinical trial.
The workshop is designed to give the participant an insight into the world of health economics, and an understanding of where health economics fits with designing clinical trials. It will introduce the participant to:
This workshop will be led by Associate Professor Rachael Morton, Director of Health Economics at the NHMRC Clinical Trials Centre and President of the Health Services Research Association of Australia and New Zealand, and health economists Blaise Agresta and Dr Mbathio Dieng.
Designed for clinician-investigators designing trials to change clinical practice and policy. No prior economics knowledge required.
Learning objectives include:
Find out more about the pre-conference workshops on the ACTA International Clinical Trials Conference website.